Filing Flows › Health Care › Schrodinger (SDGR)
Schrodinger (SDGR) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · Schrodinger (SDGR) Q3 2026 earnings results →
Q3 2026 Revenue up 19% year over year to $64.5M · 58¢ of every $1 of revenue lost · operating margin -40.5%
Schrodinger made $64.5M in Q3 2026 (+19% Y/Y): Software products and services $38.2M, Drug discovery $24.2M, Contribution $2.2M. Operating margin -40.5%, net loss $37.7M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $64.5M in Q3 2026, up 19% year over year and up 10% from the previous quarter. Drug discovery was the largest line at 38% of revenue. Drug discovery added $11.2M year over year (up 86%), 110% of the total change. Contribution declined 60%.
Gross margin was 59.3%, up 7.7 points from Q3 2025. Operating costs exceeded revenue by $26.1M, an operating margin of -40.5%. Operating expenses fell 13% while revenue rose 19%. The quarter ended with a net loss of $37.7M, after a profit of $6.0M the previous quarter.
Operating cash flow was −$47.6M. Non-cash charges added back $1.5M of depreciation and amortization and $7.9M of share-based compensation. Working capital and other items used $19.3M. Capital expenditures of $1.3M exceeded it, leaving free cash flow of −$48.9M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 4, 2026 | $64.5M | +19% | -40.5% | −$37.7M | −$47.6M |
| Q2 2026 | 10-Q | Aug 5, 2026 | $58.9M | +8% | -70.6% | $6.0M | −$34.1M |
| Q1 2026 | 10-Q | May 5, 2026 | $58.6M | -2% | -83.3% | −$60.0M | −$14.8M |
| Q4 2025 | 10-K | Feb 25, 2026 | $87.2M | -1% | -19.7% | $32.5M | −$16.1M |
| Q3 2025 | 10-Q | Nov 5, 2025 | $54.3M | +54% | -84.6% | −$32.8M | −$61.9M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $54.8M | +16% | -96.6% | −$43.2M | −$52.2M |
| Q1 2025 | 10-Q | May 7, 2025 | $59.6M | +63% | -85.5% | −$59.8M | $144M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Schrodinger
Our differentiated, physics-based computational platform enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at a lower cost, compared to traditional methods. Our software platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. We are applying our computational platform to advance a broad pipeline of drug discovery programs in collaboration with leading biopharmaceutical companies. In addition, we use our computational platform to discover novel molecules for our pipeline of proprietary drug discovery programs, which we are advancing through preclinical and clinical development.
In its own words, from its 10-K, filed Feb 25, 2026.
Schrodinger against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +19% against the peers' median +10%. Operating margin: -40.5% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| SDGR Schrodinger | Q3 2026 | $64.5M | +19% | -40.5% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Schrodinger 10-Q on SEC EDGAR · CIK 1490978 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns SDGR and who is buying
More on SDGR
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results